Of the tumors, 6.5% were “multiple‐classifiers” reflecting the fact that POLEmut or MMRd endometrial carcinomas may exhibit secondary mutations, for example in TP53, due to their ultramutated or hypermutated phenotype. This evidence concerns the gene TP53 and endometrial carcinoma.